Icosapent Ethyl
- Generic Name
- Icosapent Ethyl
- Brand Names
- Vascepa, Vazkepa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H34O2
- CAS Number
- 86227-47-6
- Unique Ingredient Identifier
- 6GC8A4PAYH
- Background
Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. FDA approved on July 26, 2012.
- Indication
作为最大耐受他汀类药物治疗的辅助手段，以降低甘油三酯（TG）水平升高（≥150mg/dL）、已确定的心血管疾病或糖尿病以及2个或更多心血管疾病风险因素的成年患者需要住院治疗的心肌梗死、中风、冠状动脉血运重建和不稳定心绞痛的风险。
- Associated Conditions
- Hospitalizations, Severe Hypertriglyceridemias
Omega-3 Supplementation and Cardiovascular Health: Mixed Results and Nuanced Benefits
• Clinical trials show mixed results regarding the benefits of omega-3 supplements in preventing major cardiovascular events, with some studies suggesting potential harm.
• A subgroup analysis of the VITAL trial indicated a 19% reduction in major CVD events among those with higher omega-3 levels, particularly in reducing heart attacks.
• The REDUCE-IT trial demonstrated a 25% reduction in major CVD events using icosapent ethyl in high-risk patients already on statins, leading to FDA approval for this specific use.
• Experts recommend a heart-healthy diet rich in fish as the primary source of omega-3s, advising caution and medical supervision for high-dose supplementation.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath